Vinay Prasad is returning to the Food and Drug Administration to lead the Center for Biologics Evaluation and Research. Prasad left the agency less than two weeks ago amid tensions over Sarepta’s (SRPT) Duchenne’s muscular dystrophy gene therapy treatment. Health and Human Services spokesperson Andrew Nixon told media outlets Saturday: “At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research.” Other gene therapy stocks include Capricor Therapeutics (CAPR), Taysha Gene Therapies (TSHA) and MeiraGTx (MGTX).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Cautious Outlook for Sarepta Therapeutics Amid Uncertain Demand and Regulatory Challenges
- Sarepta Therapeutics: Hold Rating Amid Revenue Decline and Regulatory Challenges
- Cautious Outlook on Sarepta Therapeutics Amid Financial Strain and ELEVIDYS Challenges
- Sarepta price target raised to $50 from $48 at Wells Fargo
- Sell Rating Issued for Sarepta Therapeutics Amid Uncertain Revenue Prospects and High Future Expenses